1. Home
  2. RFL vs CASI Comparison

RFL vs CASI Comparison

Compare RFL & CASI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RFL
  • CASI
  • Stock Information
  • Founded
  • RFL 2017
  • CASI 1991
  • Country
  • RFL United States
  • CASI China
  • Employees
  • RFL N/A
  • CASI N/A
  • Industry
  • RFL Real Estate
  • CASI Biotechnology: Pharmaceutical Preparations
  • Sector
  • RFL Finance
  • CASI Health Care
  • Exchange
  • RFL Nasdaq
  • CASI Nasdaq
  • Market Cap
  • RFL 65.4M
  • CASI 58.8M
  • IPO Year
  • RFL N/A
  • CASI 1996
  • Fundamental
  • Price
  • RFL $2.01
  • CASI $2.62
  • Analyst Decision
  • RFL
  • CASI Strong Buy
  • Analyst Count
  • RFL 0
  • CASI 1
  • Target Price
  • RFL N/A
  • CASI $6.00
  • AVG Volume (30 Days)
  • RFL 41.9K
  • CASI 42.2K
  • Earning Date
  • RFL 03-12-2025
  • CASI 11-15-2024
  • Dividend Yield
  • RFL N/A
  • CASI N/A
  • EPS Growth
  • RFL N/A
  • CASI N/A
  • EPS
  • RFL N/A
  • CASI N/A
  • Revenue
  • RFL $697,000.00
  • CASI $22,055,000.00
  • Revenue This Year
  • RFL N/A
  • CASI N/A
  • Revenue Next Year
  • RFL N/A
  • CASI $134.79
  • P/E Ratio
  • RFL N/A
  • CASI N/A
  • Revenue Growth
  • RFL 151.62
  • CASI N/A
  • 52 Week Low
  • RFL $1.29
  • CASI $2.05
  • 52 Week High
  • RFL $2.50
  • CASI $8.19
  • Technical
  • Relative Strength Index (RSI)
  • RFL 58.35
  • CASI 38.56
  • Support Level
  • RFL $1.83
  • CASI $2.44
  • Resistance Level
  • RFL $2.01
  • CASI $2.76
  • Average True Range (ATR)
  • RFL 0.15
  • CASI 0.29
  • MACD
  • RFL 0.02
  • CASI 0.03
  • Stochastic Oscillator
  • RFL 94.44
  • CASI 21.18

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.

About CASI CASI Pharmaceuticals Inc.

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.

Share on Social Networks: